We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock

Delisted

ATXI was delisted on the 18th of March, 2025.

34 hedge funds and large institutions have $28.1M invested in Avenue Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 1

375% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 4

79% more funds holding

Funds holding: 1934 (+15)

60% more capital invested

Capital invested by funds: $17.6M → $28.1M (+$10.6M)

Holders
34
Holders Change
+15
Holders Change %
+78.95%
% of All Funds
0.7%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
10
Reduced
1
Closed
4
Calls
Puts
Net Calls
Net Calls Change

ATXI Hedge Fund Activity: Q2 2020 in Review

34 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2020, worth a combined $28.1M — up 60% from $17.6M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ATXI positions and 4 closed out — a net gain of 15 holders — while 10 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, adding an estimated $2.73M. The largest seller was Millennium Management, exiting entirely with an estimated $631K sold.

  • 34 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2020, up from 19 in Q1 2020.
  • Funds reported $28.1M of Avenue Therapeutics, Inc. Common Stock stock for Q2 2020, up 60% quarter-over-quarter.
  • 19 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2020 and 4 closed out, a net change of +15 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $2.73M added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2020 was Millennium Management, an estimated $631K sold.

Based on aggregated 13F filings for Q2 2020.